Holocene Advisors, LP Mirati Therapeutics, Inc. Call Options Transaction History

Holocene Advisors, LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $1.93 Million - $3.85 Million	25,500 Added 7.31%	374,300 $30.8 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $2.31 Million - $3.11 Million	17,500 Added 5.28%	348,800 $61.7 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $13.1 Million - $16.4 Million	91,300 Added 38.04%	331,300 $53.5 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $19.9 Million - $27.7 Million	125,000 Added 108.7%	240,000 $41.1 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $13 Million - $19.2 Million	115,000 New	115,000 $19.1 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.